All patients
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
la/mBC - HER2 positive, HER inhibitor vs. HER inhibitor, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CLEOPATRA, 2012 0.66 [0.52; 0.84]
EGF104900, 2010 0.74 [0.57; 0.96]
HER2CLIMB, 2020 0.66 [0.50; 0.88]
LUX-Breast 1, 2016 1.48 [1.12; 1.95]
NALA, 2020 0.88 [0.72; 1.07]
NALA (brain metastases), 2020 0.90 [0.59; 1.38]
NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.62 [0.30; 1.27]
SYSUCC-002, 2022 0.82 [0.65; 1.04]
0.83 [0.69 ; 1.00 ] CLEOPATRA, 2012, EGF104900, 2010, HER2CLIMB, 2020, LUX-Breast 1, 2016, NALA, 2020, NALA (brain metastases), 2020, NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, SYSUCC-002, 2022 8 72% 3,634 moderate not evaluable deaths (OS) (extension)detailed results ALTTO (T plus L vs T), 2020 0.86 [0.70; 1.06]
CLEOPATRA, 2012 0.69 [0.58; 0.82]
NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.72 [0.41; 1.27]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.85 [0.49; 1.47]
0.76 [0.67 ; 0.86 ] ALTTO (T plus L vs T), 2020, CLEOPATRA, 2012, NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 4 0% 5,602 low not evaluable PFS (extension)detailed results CLEOPATRA, 2012 0.69 [0.59; 0.81]
0.69 [0.59 ; 0.81 ] CLEOPATRA, 2012 1 0% 808 NA not evaluable progression or deaths (PFS)detailed results CLEOPATRA, 2012 0.62 [0.51; 0.75]
EGF104900, 2010 0.74 [0.58; 0.94]
HER2CLIMB, 2020 0.54 [0.42; 0.70]
HER2CLIMB (patients with brain metastases), 2020 0.48 [0.34; 0.68]
LUX-Breast 1, 2016 1.10 [0.86; 1.41]
NALA, 2020 0.76 [0.63; 0.92]
NALA (brain metastases), 2020 0.66 [0.41; 1.06]
SYSUCC-002, 2022 0.88 [0.71; 1.09]
0.71 [0.60 ; 0.85 ] CLEOPATRA, 2012, EGF104900, 2010, HER2CLIMB, 2020, HER2CLIMB (patients with brain metastases), 2020, LUX-Breast 1, 2016, NALA, 2020, NALA (brain metastases), 2020, SYSUCC-002, 2022 8 74% 3,497 moderate not evaluable RFS/DFSdetailed results ALTTO (T plus L vs T), 2020 0.84 [0.70; 1.01]
0.84 [0.70 ; 1.01 ] ALTTO (T plus L vs T), 2020 1 0% 4,190 NA not evaluable DORdetailed results NALA, 2020 0.50 [0.33; 0.75]
NALA (brain metastases), 2020 0.47 [0.12; 1.88]
0.50 [0.34 ; 0.73 ] NALA, 2020, NALA (brain metastases), 2020 2 0% 722 moderate not evaluable events or deaths (EFS)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.78 [0.47; 1.29]
0.78 [0.47 ; 1.29 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 1 0% 301 NA not evaluable events or deaths (EFS) (extended)detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 0.81 [0.52; 1.26]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.98 [0.64; 1.51]
0.89 [0.66 ; 1.22 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 0% 604 moderate not evaluable objective responses (ORR)detailed results CLEOPATRA, 2012 10.80 [5.29; 22.05]
EGF104900, 2010 1.56 [0.68; 3.59]
LUX-Breast 1, 2016 1.04 [0.71; 1.52]
NALA (brain metastases), 2020 1.02 [0.37; 2.80]
2.07 [0.66 ; 6.50 ] CLEOPATRA, 2012, EGF104900, 2010, LUX-Breast 1, 2016, NALA (brain metastases), 2020 4 91% 1,551 moderate not evaluable pCR detailed results NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012 2.60 [1.49; 4.54]
NeoALTTO (lapatinib vs trastuzumab), 2012 0.78 [0.47; 1.30]
1.42 [0.44 ; 4.60 ] NeoALTTO (lapatinib plus trastuzumab vs trastuzumab), 2012, NeoALTTO (lapatinib vs trastuzumab), 2012 2 90% 604 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results HER2CLIMB, 2020 1.92 [0.77; 4.80]
1.92 [0.77 ; 4.80 ] HER2CLIMB, 2020 1 0% 601 NA not evaluable Anaemia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Asthenia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.31 [0.03; 3.12]
0.31 [0.03 ; 3.12 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Back pain AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Constipation AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Decreased appetite AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Diarrhoea AE (grade 3-4)detailed results NALA (brain metastases), 2020 2.48 [0.79; 7.77]
2.48 [0.79 ; 7.77 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Fatigue AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.13; 7.24]
0.98 [0.13 ; 7.24 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Headache AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Nausea AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.64 [0.10; 4.00]
0.64 [0.10 ; 4.00 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.29; 3.27]
0.98 [0.29 ; 3.27 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Pyrexia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Rash AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Stomatitis AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Vomiting AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Weight decreased AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-30 05:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 355,337,146,317
- treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308
